Related references
Note: Only part of the references are listed.Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer
Francesco Pantano et al.
SCIENTIFIC REPORTS (2020)
Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
Jie Ming et al.
FRONTIERS IN ONCOLOGY (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
Andreas Kahlmeyer et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert Motzer et al.
LANCET ONCOLOGY (2019)
被撤回的出版物: Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity (Retracted article. See vol. 11, 2022)
William C. Dougall et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
L. Derosa et al.
ANNALS OF ONCOLOGY (2018)
High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma
Andreas Seeber et al.
CANCER SCIENCE (2018)
Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC).
Manuel C. Maia et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
Elizabeth Ahern et al.
ONCOIMMUNOLOGY (2018)
An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer
Alexander Liede et al.
ONCOIMMUNOLOGY (2018)
Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma
Kosuke Ueda et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice
Elizabeth Ahern et al.
CLINICAL CANCER RESEARCH (2017)
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
Roberto Iacovelli et al.
TARGETED ONCOLOGY (2016)
Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma
Mark J. Smyth et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups
Guillermo de Velasco et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma
Alejo Rodriguez-Vida et al.
ESMO OPEN (2016)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
A Doran Bostwick et al.
Journal for ImmunoTherapy of Cancer (2015)
Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance
Imran S. Khan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Power and sample size for DNA microarray studies
MLT Lee et al.
STATISTICS IN MEDICINE (2002)
Share Paper
